Purpose | Board Meetings Date | Announcement Date |
---|---|---|
Board Meeting | 8 Aug 2025 | 1 Aug 2025 |
Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2025 inter alia to consider and approve unaudited financial results for the quarter ended 30th June 2025 and to consider any other matter with the permission of the Chairman. Appointment of Chief Marketing Officer To consider and approve the Un-audited Financial results along with Limited Review Report for the quarter ended 30th June, 2025 and appointment of Chief Marketing Officer of the company. (As per BSE Announcement Dated on 08.08.2025) | ||
Board Meeting | 23 May 2025 | 19 May 2025 |
Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 ,inter alia, to consider and approve Audited Financial Results for the Quarter and Financial Year ended 31st March, 2025, proposal of Bonus Issue, if any and subject to approval, and recommendation of Final Dividend, if any, for the Financial Year 2024-25. To consider and approve the Audited Financial Results for the Financial Year ending 31st March, 2025, issue of Bonus Equity shares in the ration of 1:1 i.e. 1 (One) equity shares of ? 5.00/- each for every 1 (One) full paid-up equity share of ? 5.00/-, recommendation of Dividend for the Financial Year, 2024-25, subject to the approval of the members. (As Per BSE Announcement Dated on :23.05.2025) | ||
Board Meeting | 7 Feb 2025 | 31 Jan 2025 |
ANUH PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve unaudited financial results for the quarter ended 31st December 2024 and to consider any other matter with the permission of the Chairman. To consider and approve the Un-audited Financial Results and Limited Review Report for the Quarter ended 31st December, 2024. (As per BSE Announcement Dated on 07/02/2025) | ||
Board Meeting | 8 Nov 2024 | 29 Oct 2024 |
Quarterly Results To consider and approve the Un-audited Financial results and Limited Review Report for the Quarter and half year ended 30th September, 2024 and approving the revised Policy for Prevention of Sexual Harassment (POSH) at Workplace as per The Sexual Harassment of Women at Workplace (Prevention, Prohibition and; Redressal) Act, 2013 (Act). (As per BSE Announcement Dated on 08/11/2024) |
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.